


ISSN: 2249-7137 Vol. 11, Issue 4, April 2021 Impact Factor: SJIF 2021 = 7.492



ACADEMICIA

An International Multidisciplinary Research Journal

(Double Blind Refereed & Peer Reviewed Journal)



DOI: 10.5958/2249-7137.2021.01069.7

EVALUATION OF THE EFFECTIVENESS OF NEUROPROTECTIVE THERAPY ON RETINAL MORPHOMETRIC PARAMETERS IN PRIMARY OPEN-ANGLE GLAUCOMA

Karimova M.Kh*; Abulkasimova Kh.Kh**

*Republican Specialized center of eye microsurgery, Tashkent, UZBEKISTAN

**Central Polyclinic Of JSC "Uzbekiston Temir Yullari", Tashkent, UZBEKISTAN

ABSTRACT

Neuroprotective therapy refers to measures preventing damage to neurons in the retina and optic nerve. It should be carried out when the damage to the nervous tissue has not yet become irreversible [2, 3, 7, 8]. We examined 60 patients (120 eyes) with POAG I, II and III stages with the duration of glaucoma from 5 to 15 years. IOP was compensated by selective laser trabeculoplasty (SLT) surgery or local hypotensive therapy treated at the Central Polyclinic of JSC " UZBEKISTON TEMIR YULLARI", Tashkent. The patients were divided into 2 groups: group 1 (control) – 30 patients (60 eyes), who received only traditional medication therapy for glaucoma. Group 2 (main) consisted of 30 patients (60 eyes) who received OMK 2 in 1 drop 3 times a day for 1 month along with traditional medical treatment. All patients underwent the w following ophthalmic examination methods with OCT, which was carried out on the device "3D OCT-1" by "Maestro 2". In this study, structural and functional progression in the control group was accompanied by a decrease in the thickness of the RNFL, GCC and the volume of the NRR. In the main group, these parameters were stable during the observation period or had a positive trend, which indicates the neuroretinoprotective effect of OMK 2. Thus, the use of OMK 2 allows improving the functional characteristics in patients with POAG. The positive effect is presumably associated with IOP control and neuroprotective properties of the medicine.

KEYWORDS: Primary Open-Angle Glaucoma, Neuroprotective Therapy, Optical Coherence Tomography, Citicoline (CDP-Choline).

Vol. 11, Issue 4, April 2021 Impact Factor: SJIF 2021 = 7.492

REFERENCES

ISSN: 2249-7137

- 1. Abulkasimova Kh.Kh., Karimova M.Kh.. Evaluation of the local antihypertensive drugs effect on the status of the morphometric parameters of the optic nerve and macula in patients with primary open-angle glaucoma/ Sovremenniye tekhnologii v oftalmologii No. 3 2019 (in Russian). «Fyodorovskiye chteniya» XVI All-Russian scientific and practical conference with international participation, 10-13 pages. doi:org/10.25276/2312-4911-2019-3-10-13
- 2. Abulkasimova Kh.Kh., Karimova M.Kh., Zakirkhodjayeva M.A. Comparative Analysis Of The Electrophysiological Indicators Of The Optic Nerve In Complex Treatment Of Patients With Primary Open-Angle Glaucoma. The American Journal of Medical Sciences and Pharmaceutical Research, 2(08), 11-17. (TAJMSPR) SJIF-5.286 DOI-10.37547/TAJMSPR.Volume 2 Issue 8, 2020. ISSN 2689-1026.
- **3.** Abulkasimova Kh.Kh., Karimova M.Kh. Citicoline applications as a complex primary treatment. Uzbek medical journal. №6 2020. DOI http://dx.doi.org/10.26739/2181-0664-2020-6-3. 18-22 pages.
- **4.** Abulkasimova Kh.Kh. Assessment of the effect of nootropic eye drops to peripheral visual field in patients with primary open-angle glaucoma. 38th Congress of the EUROPEAN SOCIIETY OF CATARACT & REFRACTIVE SURGEONS. Amsterdam 2020.
- **5.** Kasimova M.S., Madirimov I.R. Evaluation of the neuroprotective effect of combination therapy in patients with primary open-angle glaucoma (POAG). Stomatologiya No.2 (75) 2019, 64-66 pages.
- **6.** Bikbov M.M., Babushkin A.E., Orenburkina O.I. Current opportunities for the prevention of excessive scarring after antiglaucoma surgeries using antimetabolites. Natsionalniy zhurnal glaukoma. 2019; 18(3):55-60.
- **7.** E.A. Egorov, V.P. Erichev, V.V. Strakhov, S.YU. Petrov, T.B. Romanova, M.V. Vasina, V.S. Zinina, A.S. Makarova, S.YU. Kazanova, A.V. Yartsev. Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy. Vestnik Oftalmologii No.3, 2019, 20-30 pages.
- **8.** Korelina V.E., Chekurova L.V., Lauta V.F. POSSIBILITIES OF NEUROPROTECTION IN GLAUCOMA. Conference Glaucoma: theory and practice. Horizons of neuroprotection. Collection of scientific articles, St. Petersburg 2014. Issue No. 9, 43-47 pages.
- **9.** Lavinsky F, Wu M, Schuman JS, et al. Can macula and optic nerve head parameters detect glaucoma progression in eyes with advanced circumpapillary retinal nerve fiber layer damage? Ophthalmology 2018; 125:12:1907.
- **10.** Petrova K., Anguelov B. Diagnostic accuracy of ganglion cell complex parameters in early, moderate advanced glaucoma // Bulgarian forum glaucoma. 2014. V. 4. № 2. P. 53-58.
- **11.** Ahmad A. Aref, MD, MBA, Anand Bhatt, Ian Conner, MD, PhD and Samuel Asanad, MD. American Academy of ophthalmology. Neuroprotection in Glaucoma. By Ian Conner, MD, PhD on April 22, 2020.



ISSN: 2249-7137 Vol. 11, Issue 4, April 2021

Impact Factor: SJIF 2021 = 7.492

- **12.** Banegas SA, Anton A, Morilla A, et al. Evaluation of the retinal NFL thickness, the mean deviation, and the visual field index in progressive glaucoma. J Glaucoma 2016; 25:3:e229-e235.
- **13.** Gandolfi S, Marchini G, Caporossi A, et al. Cytidine 5'-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients. 2020; 12(3).
- **14.** Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 2002 Apr; 28(4):353–69. https://doi.org/10.1081/ddc-120002997 PMID: 12056529.
- **15.** Kaushik S., Pandav S.S., Ram J. Neuroprotection in glaucoma. J Postgrad Med 2003; 49(1):90–95.
- **16.** Lee WJ, Baek SU, Kim YK, et al. Rates of ganglion cell-inner plexiform layer thinning in normal, open-angle glaucoma and pseudoexfoliation glaucoma eyes: A trend-based analysis. Investig Ophthalmol Vis Sci 2019;60:2:599-604.
- 17. Mori S., Hangai M., Nakanishi H., Kotera Y., Inoue R., Morishita S., Aikawa Y., Hirose F., Ojima T. Measurement by spectral domain optical coherence tomography for glaucoma diagnosis N. Yoshimura Kyoto University. Kyoto, Japan. IOVS. 2008. Suppl. 4651 P. 368–375.
- **18.** Roberti G, Tanga L, Parisi V, et al. A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy. Indian J. Ophthalmol. 2014; 62:549–553.
- **19.** Xu X, Xiao H, Guo X, et al. Diagnostic ability of macular ganglion cell-inner plexiform layer thickness in glaucoma suspects. Med (United States) 2017; 96:51:e9182.